The goal of this observational study is to collect detailed long-term real-world data and biomaterials from men with high-risk localized prostate cancer and synchronous metastatic hormone-sensitive prostate cancer. This will help to better understand how these patients are treated in daily practice, how treatments affect quality of life, and facilitate biomarker discovery. The infrastructure is also designed to enable future cohort multiple randomized controlled trials.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Treatment patterns
Timeframe: From diagnosis through study completion, up to 4 years
PSA response
Timeframe: From treatment initiation up to 12 months.
PSA nadir
Timeframe: From treatment initiation up to 12 months
Utilization of imaging modalities for primary staging
Timeframe: At baseline
Time to clinical progression
Timeframe: From treatment initiation through study completion, up to 4 years
Time to biochemical progression
Timeframe: From treatment initiation through study completion, up to 4 years
Time to radiographic progression
Timeframe: From treatment initiation through study completion, up to 4 years
Time to castration-resistant prostate cancer (CRPC)
Timeframe: From treatment initiation through study completion, up to 4 years
Overall survival
Timeframe: From diagnosis through study completion, up to 4 years
Adverse events
Timeframe: From treatment initiation through study completion, up to 4 years
Number of hospital admissions
Timeframe: From treatment initiation through study completion, up to 4 years
Number of outpatient visits
Timeframe: From treatment initiation through study completion, up to 4 years